Compare Principal Financial Group Inc Common Stock (PFG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Principal Financial Group Inc Common Stock vs Tango Therapeutics Inc. — how do they compare? Principal Financial Group Inc Common Stock trades at $108.26 (market cap $23.04B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Principal Financial Group Inc Common Stock is far larger — about 6.1× Tango Therapeutics Inc.'s market cap, and Principal Financial Group Inc Common Stock pays a 3.12% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Principal Financial Group Inc Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| PFG | TNGX | |
|---|---|---|
Market Cap | $23.04B | $3.75B |
Volume | 1,066,568 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $118.51 | $32.90 |
52-Week Low | $78.39 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $22.12B | $2.77B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Principal Financial Group (PFG) trades at $107.64, down 0.19% with a bearish technical outlook. The stock shows mixed fundamentals with recent earnings beats but faces valuation concerns at a P/E of 15.33. Recent acquisition of Beam Benefits aims to expand digital capabilities in specialty benefits, while analyst sentiment remains cautious with a 'Hold' consensus rating and $108.33 price target.
PFG presents a balanced risk-reward profile with steady revenue growth and improving profit margins, but faces headwinds from technical weakness and mixed analyst sentiment. The Beam Benefits acquisition provides growth potential in the SMB market, though execution risks and competitive pressures in the multiline insurance sector warrant monitoring for investors seeking exposure to financial services.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Principal Financial Group Inc Common Stock
Principal Financial Group provides retirement, insurance, and asset management services. It serves individuals, employers, and institutional clients.
Read more on PFG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
